CLOs on the Move

Fond Du Lac Lutheran Home Inc

www.fdllutheranhome.org

 
Fond Du Lac Lutheran Home Inc is a Fond Du Lac, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Upfront Healthcare Services

Upfront`s Care Traffic Control platform proactively reassures and directs patients to the safest and most relevant care options within the health system.

OrthoIndy

OrthoIndy is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TrialCard

TrialCard offers customized patient access solutions exclusively for the pharmaceutical industry in support of product marketing, patient assistance programs, and phase IV clinical trials. TrialCard innovates by focusing on client brands and analyzing new trends in prescription optimization for both insured, and uninsured patients.

City of Winston-Salem, NC

City of Winston-Salem, North Carolina, U.S.A. Local government. Contact City Link call 311; citylink@cityofws.org

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.